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The role of calcium, lipid membranes and islet amyloid
polypeptide in the onset of type 2 diabetes: innocent
bystanders or partners in a crime?
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INTRODUCTION
Type II diabetes mellitus (T2DM) is one of
the most disabling age-related pathologies
in developed countries (1). Its incidence is
constantly growing: the number of people
affected by T2DM worldwide grew from 28
million cases in 1985 to around 168 million
in 2001, with an estimate of 350 million
cases in 2030 (2).
Despite the intense research efforts
focusing on T2DM in the last 20 years, the
cause of the underlying pathology is still
unclear. Islet Amyloid Polypeptide (IAPP)
is an amyloidogenic protein, member of the
calcitonin family (3), which is known to
be involved in the mechanisms lying at the
root of T2DM pathogenesis (4, 5). Indeed,
although the correlation between islet β-
cell death and amyloid fibril formation
is still a matter of debate, recent studies,
performed on transgenic mice, show that
IAPP aggregation can mediate β-cell fail-
ure in T2DM (6). Indeed, despite human
and rat variants of IAPP differing by only
six amino acids, the two variants behave
in a completely different way. In particular,
rat IAPP (rIAPP) is unable to form amy-
loid aggregates under normal conditions
(7) and rats do not develop T2DM in anal-
ogous conditions. Human IAPP (hIAPP)
amyloid aggregates are detectable in pan-
creas’ extracellular space in 90% of patients
(4), while only 10% of patients do not have
detectable amyloid deposits.
We propose that T2DM etiology might
be clarified by studying the close relation-
ships between three apparently indepen-
dent issues: (i) amyloid toxicity; (ii) genetic
factors; and (iii) environmental risk factors
related to lifestyle and diet.
MECHANISMS OF IAPP-INDUCED
MEMBRANE DISRUPTION
The mechanisms by which amyloid inter-
mediates (Aβ peptide, hIAPP, and other
amyloid-forming proteins) cause cyto-
toxicity and disease remains unsolved,
although some recent studies (8) suggest
that the water/membrane interface is crit-
ical for influencing amyloid aggregation.
Of note, mature amyloid fibrils are pre-
sumed to be inert while small oligomeric
intermediates are suggested to penetrate
the cell membrane (9). It has been hypoth-
esized that amyloid-forming peptides may
cause membrane damage by: (a) changing
the bilayer fluidity, (b) generating protein-
stabilized pores (poration), (c) laying on
one leaflet of the membrane (carpeting),
or (d) removing lipid components from
the bilayer by detergent-like mechanisms
(10). It has also been shown that the for-
mation of amyloid fibers occurs indepen-
dently of membrane leakage and that mem-
brane composition and the presence of ions
may have a major influence on amyloid-
mediated membrane damage (11).
In recent years, several studies have
focused on the interpretation of molecu-
lar mechanisms underlying T2DM. In par-
ticular, researchers investigated the inter-
action between hIAPP and phospholipid
membranes, a process that seems to be
correlated to the loss of pancreatic β-cells
(12–15). The most recent results suggest
that hIAPP-induced membrane disruption
could be described as a two independent
step process. The first step is correlated with
pore formation occurring after the inser-
tion of monomeric or oligomeric species
inside the membrane hydrophobic core.
The insertion of a protein into a mem-
brane interferes with lipid packing and,
at high concentration, it might result in
a local bending deformation. To mini-
mize the energetically unfavorable defor-
mation, proteins tend to cluster (16). The
second step of membrane disruption is
correlated with the growth of fibers onto
the membrane surface, which causes com-
plete membrane dissolution through a
detergent-like mechanism (13, 17).
Since the two steps are independent
processes, they might be separately tar-
geted by novel therapeutic approaches.
The membrane lipid composition has been
shown to be a critical point for the mech-
anism of membrane disruption medi-
ated by hIAPP. The presence of phos-
phatidylethanolamine headgroup lipids,
for example, can modulate the entity of
the first and second step of membrane
disruption. Also, the presence of cho-
lesterol could finely regulate membrane
dissolution by both inhibiting the affin-
ity of hIAPP for the membrane as well
as its insertion in the bilayer. Unfortu-
nately, to date there are a lack of stud-
ies that have systematically investigated
the role played by membrane composition
(i.e., length of hydrophobic tails, percent-
age of cholesterol, presence of different
lipid headgroups) on hIAPP/membrane
interactions.
Therefore, the membrane disruption
mechanism can be regulated by sev-
eral factors, such as metal ions balance,
increased hIAPP secretion, the presence
of free fatty acid, etc. which could arise
from genetic predisposition, lifestyle, and
diet.
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GENETIC RISK FACTORS IN THE
DEVELOPMENT OF T2DM: INSULIN
AND CALCIUM RECEPTORS
Despite enormous efforts, the precise
identification of the genetic determi-
nants responsible for T2DM still remains
unsolved. T2DM is not considered a
genetic disease. Although recent papers
demonstrate that the S20G mutation in
the primary structure of hIAPP leads to
an early variant of T2DM (18, 19), the
incidence of this variant is very small com-
pared to the number of patients affected
by T2DM that do not show mutations
in the hIAPP sequence. Moreover, stud-
ies focusing on the search for genetic fac-
tors involved in insulin resistance were
inconclusive. For instance, defects on
insulin receptors (INSR), correlated with
insulin resistance, have been associated
with T2DM, but only 3–4% of these
patients show mutations of INSR genes
(20). Other genes involved in triggering
insulin resistance have been discovered:
glucokinase regulatory protein (GKRP)
(21), and insulin-like growth factor-I (IGF-
I) (22). It has been reported that calpain-10
and later transcription factor 7-like two
genes in affected individuals increase the
risk to develop T2DM (23).
Recently, genetic factors involved in cal-
cium dyshomeostasis have attracted much
attention of scientists. It was noted that
patients affected by familial hypercalciuric
hypercalcemia, a genetic disease related to a
reduction of calcium receptor gene expres-
sion, are much more prone to developing
T2DM (24). This evidence supports a key
role played by genetic factors regulating
calcium dyshomeostasis in the develop-
ment of T2DM. It is tempting to suggest
that high plasma Ca2+ levels may acti-
vate pathogenic molecular mechanisms
involving hIAPP-mediated membrane dis-
ruption, as already reported in literature
(11, 25). It has been reported that there
is an increase in the intracellular calcium
ion concentration ([Ca2+]i) in diabetic
subjects (26, 27). Notably, dysregulation of
[Ca2+]i in the cells of several tissues spon-
taneously occurs during aging as well as
in obese people (28–30). Dyshomeostasis
of intracellular Ca2+ can affect several
membrane-related functions, such as
domain organization, vesicular trafficking,
and membrane adhesion/fusion (31, 32). A
correlation between Ca2+ dyshomeostasis
and hIAPP–membrane interaction (11, 25)
has also been shown. In particular, it was
observed that an increase of Ca2+ con-
centration facilitates hIAPP penetration
into the phospholipid membrane to form
pores (11).
WEIGHT GAIN AND T2DM: THE ROLE OF
FREE FATTY ACIDS
Several lifestyle factors, which characterize
the most developed countries, affect the
incidence of T2DM (33, 34). For exam-
ple obesity or, more generally, weight gain,
significantly increase the risk of develop-
ing the disease (35–37). Other risk factors
are physical inactivity (35), habitual energy
intake in relation to expenditure (35), com-
position of the diet (38, 39), and metabolic
characteristics (35).
Insulin resistance, which is actually con-
sidered the starting point for the develop-
ment of T2DM, is strictly correlated with
weight gain (40, 41). From a molecular
point of view, obesity leads to calcium
dyshomeostasis (30), increased concentra-
tion of free fatty acids (FFA) (42), and
cholesterol (43, 44). All of these effects have
been shown to be involved in the molecular
mechanisms leading to hIAPP-induced dis-
ruption of Langerhans’ β-cells (11, 25, 45,
46). Thus, these metabolic effects could all
represent a common link between environ-
mental factors and molecular mechanisms.
Plasma FFA concentration is usually ele-
vated in obesity. It is worth noting that
FFA may have a deep influence on Ca2+
homeostasis, which in turn triggers lipo-
toxic pathways leading to T2DM (47).
Also, it has been shown that elevated FFA
can cause insulin resistance and thus rep-
resents a common link between obesity,
insulin resistance, and the development
of T2DM. Elevation of plasma FFA lev-
els in obesity is contributed by increased
FFA release from enlarged adipose tissue,
and reduced FFA clearance (48). Insulin
resistance induced by high levels of FFA
results in hyperinsulinemia and increased
secretion of hIAPP. In turn, an increase
in the local concentration of hIAPP medi-
ates a more efficient interaction with the
membrane resulting in pore formation and
fibril elongation on the membrane sur-
face (13). This conclusion is in agreement
with previous studies demonstrating that
high FFA concentrations enhance hIAPP
fibrillogenicity (49).
To overcome the poor availability of
isolated human islets, hIAPP-expressing
transgenic mice were recently employed
to investigate the role of high-fat diet on
hIAPP amyloidosis. However, it is worth
noting that amyloid growth in hIAPP-
expressing transgenic mice and in human
islets may significantly differ (50) since in
human islets the amyloid aggregation starts
intracellularly, while in transgenic mice
amyloid growth is predominantly extra-
cellular. It is important to point out that
the diverse observations regarding whether
hIAPP aggregation occurs intraceullarly or
extraceullarly may likely depend on differ-
ing in vivo metabolic environments. It is
tempting to speculate that differences in
membrane lipid composition of rodents
and human beings may play a major role
in differentiating hIAPP behavior (51).
FUTURE PERSPECTIVES
T2DM is a pathology in which several fac-
tors are tightly interconnected. Mounting
evidence points to a relationship between
hIAPP amyloid, calcium dysregulation,
membrane damage, and β-cell death. To
date, inhibition of IAPP amyloid growth
has been a matter of major interest. Over-
all, researcher efforts focusing on the design
of molecules targeting hIAPP amyloid have
been useful in providing different classes of
anti-T2DM candidates (6, 52), however, to
date, none of these compounds have been
selected for clinical trials. Nowadays, the
increasing knowledge of the mechanism
of hIAPP toxicity moves the focus toward
the development of molecules that can
halt amyloid-mediated membrane dam-
age. Since a two steps mechanism for mem-
brane disruption mediated by hIAPP has
been proposed, an efficient drug should
inhibit both poration and fiber formation
on membrane surface. However, there is
still a lack of knowledge about the cross
correlation of genetic, lifestyle and diet
effects.
The use of model membranes allows
researchers to study a simpler system than
cells and to isolate single parameters affect-
ing the process. An oversimplification in
terms of lipid composition could lead,
however, to misleading results. In order to
fit in vitro and in vivo experiments with
the process occurring in people affected
by T2DM, future cell-free experiments
should thus take into account the effects
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of genetic factors, lifestyle and diet. In par-
ticular, the effect of: (i) membrane com-
position, (ii) calcium ions, and (iii) FFA
should be addressed by biophysical meth-
ods including Thioflavine T (ThT) flu-
orescence assays, dye-leakage, solid state
NMR experiments, and large scale mol-
ecular simulations with the aim of pro-
viding a molecular description of the cas-
cade of pathogenic events occurring upon
hIAPP aggregation at water/lipid inter-
faces. Hopefully, these studies will help to
effectively design and screen an increas-
ingly large number of new compounds able
to inhibit hIAPP aggregation also in the
presence of lipid interfaces mimicking cell
membranes and, in turn, to better manage
IAPP toxicity in humans.
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